To date, only endothelin receptor antagonists (ERA), which block both ETAR and ETBR, have been successfully used to treat vasculopathic manifestations in SSc, such as PAH and DUs [86,87]. This evidence concerns the gene EDNRA and pulmonary arterial hypertension.